T. Rowe Price Associates
FULC icon

T. Rowe Price Associates’s Fulcrum Therapeutics FULC Stock Holding History

T. Rowe Price Associates’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Buy
94,235
+14,066
+18% +$85.6K ﹤0.01% 2794
2026
Q1 		$615K Buy
80,169
+16,409
+26% +$152K ﹤0.01% 2358
2025
Q4 		$722K Sell
63,760
-2,132
-3% -$21.7K ﹤0.01% 2228
2025
Q3 		$607K Sell
65,892
-3,136
-5% -$22.7K ﹤0.01% 2296
2025
Q2 		$475K Sell
69,028
-1,140
-2% -$6.1K ﹤0.01% 2327
2025
Q1 		$203K Buy
70,168
+17,800
+34% +$65.4K ﹤0.01% 2628
2024
Q4 		$247K Buy
52,368
+16,656
+47% +$61.4K ﹤0.01% 2597
2024
Q3 		$128K Hold
35,712
– – ﹤0.01% 2774
2024
Q2 		$222K Buy
35,712
+19,812
+125% +$150K ﹤0.01% 2552
2024
Q1 		$151K Hold
15,900
– – ﹤0.01% 2694
2023
Q4 		$108K Hold
15,900
– – ﹤0.01% 2707
2023
Q3 		$71K Sell
15,900
-5,300
-25% -$23.2K ﹤0.01% 2724
2023
Q2 		$70K Sell
21,200
-15,261
-42% -$44.8K ﹤0.01% 2758
2023
Q1 		$104K Sell
36,461
-114,048
-76% -$1.02M ﹤0.01% 2680
2022
Q4 		$1.09M Buy
150,509
+105,904
+237% +$691K ﹤0.01% 1730
2022
Q3 		$361K Buy
44,605
+14,888
+50% +$107K ﹤0.01% 2292
2022
Q2 		$146K Buy
29,717
+4,512
+18% +$44.1K ﹤0.01% 2674
2022
Q1 		$596K Sell
25,205
-109,550
-81% -$1.55M ﹤0.01% 2262
2021
Q4 		$2.38M Buy
134,755
+90,355
+204% +$1.79M ﹤0.01% 1647
2021
Q3 		$1.25M Buy
+44,400
New +$841K ﹤0.01% 1936

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's FULC Position: Q2 2026 in Review

T. Rowe Price Associates increased its Fulcrum Therapeutics (FULC) stake by 18% in Q2 2026, buying an estimated $85.6K and bringing the position to 94,235 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #2794.

T. Rowe Price Associates first reported a position in FULC in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.38M in Q4 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • T. Rowe Price Associates held 94,235 shares of Fulcrum Therapeutics worth $345K as of Q2 2026.
  • T. Rowe Price Associates bought 14,066 Fulcrum Therapeutics shares in Q2 2026, an estimated $85.6K.
  • Fulcrum Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2794 holding.
  • T. Rowe Price Associates first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Fulcrum Therapeutics position peaked at $2.38M in Q4 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.